Rheumatic Side Effects of Immune Checkpoint Inhibitors Often Severe, Study Reports

Patients treated with immune checkpoint inhibitors (ICIs) for various cancers are increasingly experiencing rheumatic immune‑related adverse events (rh‑irAEs), a study released online on September 8 in ACR Open Rheumatology reports. The research found that most rh‑irAEs are moderate to severe in severity, and more than one‑third of affected individuals had to discontinue ICI therapy permanently because of these complications.

The investigators analyzed clinical data from a large cohort of ICI recipients and identified a range of rheumatic manifestations—including arthritis, myositis, and vasculitis—that frequently required aggressive immunosuppressive treatment. The high rate of treatment cessation underscores the challenge of balancing the oncologic benefits of ICIs against the risk of debilitating rheumatic toxicity, and it highlights the need for early recognition and multidisciplinary management of these adverse events.

These findings suggest that rheumatologists and oncologists must collaborate closely to monitor for rh‑irAEs and to develop strategies that preserve cancer control while minimizing irreversible treatment interruption. The study adds to growing evidence that vigilant assessment and timely intervention are essential for optimizing outcomes in patients receiving immune checkpoint blockade.